At the time of writing, Pliant Therapeutics Inc [PLRX] stock is trading at $13.65, up 17.67%. An important factor to consider is whether the stock is rising or falling in short-term value. The PLRX shares have gain 18.39% over the last week, with a monthly amount glided 15.29%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Overweight rating on December 08, 2023, and set its price target to $41. On May 18, 2023, Canaccord Genuity initiated with a Buy rating and assigned a price target of $48 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $44 on April 13, 2023. Stifel initiated its recommendation with a Buy and recommended $33 as its price target on December 14, 2022. JP Morgan started tracking with a Overweight rating for this stock on December 07, 2022, and assigned it a price target of $42. In a note dated September 01, 2022, Citigroup initiated an Buy rating and provided a target price of $36 on this stock.
For the past year, the stock price of Pliant Therapeutics Inc fluctuated between $10.22 and $19.62. Currently, Wall Street analysts expect the stock to reach $39.71 within the next 12 months. Pliant Therapeutics Inc [NASDAQ: PLRX] shares were valued at $13.65 at the most recent close of the market. An investor can expect a potential return of 190.92% based on the average PLRX price forecast.
Analyzing the PLRX fundamentals
According to Pliant Therapeutics Inc [NASDAQ:PLRX], the company’s sales were 0.00M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 0.45% with Operating Profit Margin at -42.92%, Pretax Profit Margin comes in at -38.31%, and Net Profit Margin reading is -38.31%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.41 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.14 points at the first support level, and at 10.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.58, and for the 2nd resistance point, it is at 15.51.
Ratios To Look Out For
It is important to note that Pliant Therapeutics Inc [NASDAQ:PLRX] has a current ratio of 14.47. On the other hand, the Quick Ratio is 14.47, and the Cash Ratio is 2.6.
Transactions by insiders
Recent insider trading involved Lefebvre Eric, Chief Medical Officer, that happened on Jul 10 ’24 when 12319.0 shares were sold. Chief Business Officer, Hull Hans completed a deal on Jul 10 ’24 to sell 9900.0 shares. Meanwhile, Chief Financial Officer Cummings Keith Lamont sold 10911.0 shares on Jul 10 ’24.
